A new way to address missing data in late-stage clinical trials

被引:0
|
作者
Ganju, Jitendra [1 ]
Yu, Ron Xiaolong [2 ]
机构
[1] Ganju Clin Trials LLC, San Francisco, CA 94109 USA
[2] Gilead Sci, Biostat, Foster City, CA USA
关键词
Benefit-risk; Mann-Whitney method; Missing data; Win ratio; COMPOSITE END-POINTS; WIN RATIO APPROACH; OUTCOMES;
D O I
10.1016/j.cct.2024.107750
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
According to ICH E9(R1), defining the estimand comes before defining the analysis approach, and the strategies for addressing intercurrent events are key components of the estimand. With the composite strategy, the problem of missing data disappears, because it becomes part of the endpoint definition. It is this perspective that we adopt in addressing the problem of missing data. We propose comparing patients in a pairwise manner to determine which patient fared better, one patient from each group, taking into account the reason for and timing of missingness. For purposes of illustration, reasons for missingness are placed into three categories: (1) death or adverse events, (2) administration of rescue medication (treated as missing even if patient continues in the study, or a poor score is assigned), and (3) other reasons such as loss to follow-up or withdrawal of consent. Each pair of patients is compared on the endpoint of interest. The comparison outcomes are determined based on the presence of missing data, its category, and timing. For instance, if both patients in a pair have received rescue medication, the patient with the later time of rescue medication is considered to have fared better. The overall treatment effect is estimated from combining results across all pairwise comparisons. This method allows the reason and timing of missing data to contribute to the assessment of treatment effects, providing a solution to some limitations of existing methods. Thus, the pairwise comparison approach addresses the missing data problem transparently via the composite strategy.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Designing cancer screening trials for reduction in late-stage cancer incidence
    Zhu, Kehao
    Zhao, Ying-Qi
    Zheng, Yingye
    BIOMETRICS, 2024, 80 (03)
  • [32] Study design, result reporting and publication of late-stage cardiovascular trials
    Kapelios, C.
    Naci, H.
    Vardas, P.
    Mossialos, E.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3568 - 3568
  • [33] New funding needed for late-stage vaccine work?
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (08) : 573 - 573
  • [34] NEW DRUG FOR LATE-STAGE, METASTATIC BREAST CANCER
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2011, 111 (03) : 22 - 22
  • [35] New funding needed for late-stage vaccine work?
    Asher Mullard
    Nature Reviews Drug Discovery, 2019, 18 (8) : 573 - 573
  • [36] Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials
    Geary, Bethany
    Peat, Erin
    Dransfield, Sarah
    Cook, Natalie
    Thistlethwaite, Fiona
    Graham, Donna
    Carter, Louise
    Hughes, Andrew
    Krebs, Matthew G.
    Whetton, Anthony D.
    CANCERS, 2021, 13 (10)
  • [37] Choosing estimands in clinical trials with missing data
    Mallinckrodt, Craig
    Molenberghs, Geert
    Rathmann, Suchitrita
    PHARMACEUTICAL STATISTICS, 2017, 16 (01) : 29 - 36
  • [38] Handling missing data in clinical trials: An overview
    Myers, WR
    DRUG INFORMATION JOURNAL, 2000, 34 (02): : 525 - 533
  • [39] Missing repeated measures data in clinical trials
    Pugh, Stephanie L.
    Brown, Paul D.
    Enserro, Danielle
    NEURO-ONCOLOGY PRACTICE, 2022, 9 (01) : 35 - 42
  • [40] Dealing With the Missing Data Challenge in Clinical Trials
    Permutt, Thomas
    Pinheiro, Jose
    DRUG INFORMATION JOURNAL, 2009, 43 (04): : 403 - 408